Goldman Sachs Upgrades Bristol-Myers Squibb Co. (BMY) to Conviction Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Cipla Announces Settlement of REVLIMID® (lenalidomide) Capsules Patent Litigation
December 11, 2020 8:03 AM ESTMUMBAI, India, Dec. 11, 2020 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA) ("Cipla") today announced the settlement of its litigation with Celgene Corporation, and wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY) relating to patents for REVLIMID® (lenalidomide). As part of the settlement, the Parties will file Consent Judgments with the United States District Court for the District of New Jersey that enjoin Cipla from marketing generic lenalidomide before the expiration of the patents-in-suit, except as provided for in the settlement, as... More
Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
December 11, 2020 7:15 AM ESTIf approved, Inrebic will become the first new therapy for myelofibrosis in Europe in nearly a decade
Inrebic, if approved, will also be the first once-daily, oral therapy to demonstrate clinically meaningful spleen and symptom response for patients with myelofibrosis where treatment with ruxolitinib has failed or who are JAK inhibitor naïve
PRINCETON, N.J.--(BUSINESS... More
Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) with Cipla
December 11, 2020 6:59 AM ESTCipla licensed to sell volume-limited amounts of generic lenalidomide in the U.S. beginning on a confidential date after March 2022
Cipla also licensed to sell generic lenalidomide in the U.S. without volume limitation no earlier than January 31, 2026
The earliest licensed entry of any generic lenalidomide in the U.S. continues to be March 2022, based on settlements reached
NEW YORK--(BUSINESS WIRE)--
... More